BioSpace News Archive

Catalyst Pharmaceuticals, Inc. today announced that it will release its fourth quarter and full-year 2023 financial results after the market close on February 28, 2024.

Ocuphire Pharma, Inc. today announced the appointments of Ash Jayagopal, Ph.D. M.B.A. as Chief Scientific and Development Officer, and Nirav Jhaveri, C.F.A., M.B.A. as Chief Financial Officer, effective today.

Provectus Biopharmaceuticals, Inc. announced that it has engaged IR Labs, Inc. to develop a comprehensive investor relations and corporate communications program for the Company.

Vessi Medical Ltd. (“Vessi”) announced today that it has closed a Series A financing round of $16.5 million for its cryotherapy technology to treat Non Muscle Invasive Bladder Cancer (“NMIBC”).

Hemogenyx Pharmaceuticals plc announces that it has demonstrated in vivo that its proprietary Chimeric Bait Receptor can be delivered intranasally in the form of messenger RNA for the potential treatment of airborne viral infections.

Grifols announced that Biotest’s positive topline results from AdFIrst, its phase 3 clinical trial of its fibrinogen concentrate, BT524, advance this potential treatment for acquired fibrinogen deficiency, an underserved growth market.

Ono Pharmaceutical Co., Ltd. announced that it has entered into a drug discovery collaboration and option agreement with Shattuck Labs, Inc. to generate bifunctional fusion proteins for pathways involved in autoimmune and inflammatory diseases.

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, provided the following update on the Phase III clinical trial, Flamingo-01.

Larimar Therapeutics, Inc. announced the pricing of its previously announced underwritten public offering of 17,162,472 shares of its common stock at a price to the public of $8.74 per share, the closing price of its common stock on February 13, 2024, for gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses.

Sage Therapeutics, Inc. (Nasdaq: SAGE), a biopharmaceutical company leading the way to create a world with better brain health, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2023.